Sedopax
Natural health product licensed in Canada
- Licence holder
- Star-Pharma Pan-America Inc.
- NPN or DIN-HM
- 80066407
- Status
- Active licence
- Licence date
- 14 January 2016
- Revision date
- 14 September 2016
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Valeriana officinalis L.: L'absence de valépotriates doit être prouvée par des rapports d'analyse. L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Valeriana officinalis Source : Racine et rhizome Extraction ratio : 12:1 Dry plant equivalent : 720 mg Potency : 0.48 mg Valerenic acid | 60 mg | Not calculated |
| Humulus lupulus Source : Humulus lupulus - Strobile Extraction ratio : 5:1 Dry plant equivalent : 200 mg Potency : 0.04 mg 8-prenylnaringenin | 40 mg | Not calculated |
| Passiflora incarnata Source : Passiflora incarnata - Herb top Extraction ratio : 5:1 Dry plant equivalent : 200 mg Potency : 0.64 mg Flavonoids as hyperoside | 40 mg | Not calculated |
| N-acétyl-5-méthoxytryptamine Source : Mélatonine | 1 mg | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Phosphate de tricalcium, Croscarmellose de sodium, Cellulose microcristalline, Amidon de blé, Silicate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Comprimé | 1 day |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps to reduce the time it takes to fall asleep (sleep onset latency aspect of sleep quality) in people with delayed sleep phase disorder. Helps re-set the body's sleep-wake cycle (aspect of the circadian rhythm).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80066407
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2016. Photograph the packaging to check whether it has changed. Photograph the packaging